CDTX Cidara Therapeutics

Cidara Therapeutics to Present at the 2020 American College of Clinical Pharmacy (ACCP) Annual Meeting

Cidara Therapeutics to Present at the 2020 American College of Clinical Pharmacy (ACCP) Annual Meeting
EN
13/10/2020

Underlying

CDTXCidara Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cidara Therapeutics

 PRESS RELEASE
Free
CDTX Cidara Therapeu...

Cidara Therapeutics Provides Corporate Update and Reports Third Quarte...

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results Announced expanded and accelerated Phase 3 Plan for CD388, its non-vaccine influenza preventative therapeuticEnrolled and dosed first patients in Phase 3 ANCHOR study; target enrollment on track for completion in the Northern Hemisphere by December 2025; Phase 3 initiation triggered $45.0 million milestone payment to JanssenBARDA award to support expanded manufacturing and clinical development of CD388FDA granted Breakthrough Therapy designation to CD388Conference call and webcast today at 5:00 PM...

November 6, 2025 1 EN
 PRESS RELEASE
Free
CDTX Cidara Therapeu...

Cidara Therapeutics to Participate in November Investor Conferences

Cidara Therapeutics to Participate in November Investor Conferences SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below November investor conferences. Details are as follows: Event: Guggenheim 2nd Annual Healthcare Innovation ConferenceDate: November 11, 2025Time: 8:00 AM ETFormat: Fireside Chat Event: Jefferies London Healthcare Conference Date: November 17, 2025Time:...

October 28, 2025 1 EN
 PRESS RELEASE
Free
CDTX Cidara Therapeu...

Cidara Therapeutics to Report Third Quarter 2025 Financial Results and...

Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025 SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its third quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, November 6, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss...

October 23, 2025 1 EN
 PRESS RELEASE
Free
CDTX Cidara Therapeu...

Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 1...

Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025 SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it gave a late-breaking presentation on its non-vaccine influenza preventative candidate, CD388, at the European Scientific Working Group on Influenza (ESWI)’s 10th Influenza Conference taking place October 20-23, 2025 in Valencia, Spain. “We are encouraged by the trans...

October 23, 2025 1 EN
 PRESS RELEASE
Free
CDTX Cidara Therapeu...

Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation...

Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025 SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it presented late-breaking Phase 2b clinical data on its non-vaccine influenza preventative candidate, CD388, during ID Week 2025, taking place October 19-22, 2025, in Atlanta, GA. “We are pleased to share additional data from our Phase 2b NAVIGATE study at ID Week which furt...

October 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch